Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 37.8% from a year ago

Cash & equivalents stood at $26.05M at the end of Q1 FY2026, up 37.8% from a year earlier and down 8.6% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Cash & equivalents amounted to 18.0% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +37.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.05M-8.6% QoQ
Last fiscal yearDec 2025
$28.49M+65.7% YoY
Year agoMar 2025
$18.9M+37.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.8%——
1 year+65.7%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
28.49M USD
Year-over-year change
+65.7%
4-year CAGR
+3.3%

Cash & Equivalents vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +37.8% is the 3rd highest of 10, against a peer median of -3.5%.
  • Cash & equivalents amounts to 18.0% of total assets for CRBP, versus a peer median of 36.8%.
CRBP Competitors
Cash & Equivalents for CRBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MOLNMolecular Partners AGMar 2026CHF 78.53M CHF-3.5%-2.0%89.9%
ALECAlector, Inc.Mar 2026$76.96M USD+102.7%-24.7%32.1%
MISTMilestone Pharmaceuticals Inc.Mar 2026$71.32M USD+58.2%+112.3%36.8%
FBRXForte Biosciences, Inc.Mar 2026$58.22M USD+27.0%+23.3%86.6%
PEPGPepGen Inc.Mar 2026$42.15M USD-3.4%-30.7%27.0%
IPHAInnate Pharma S.A.Dec 2025€28.08M EUR-57.7%-30.7%44.8%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$26.05M USD+37.8%+18.8%18.0%
ELTXElicio Therapeutics, Inc.Mar 2026$14.95M USD-18.5%+33.5%65.9%
RANIRani Therapeutics Holdings, Inc.Mar 2026$9.64M USD-4.6%-11.7%18.6%
CRDFCardiff Oncology, Inc.Mar 2026$8.54M USD-64.5%+2.2%17.4%
Peer median (excluding CRBP) —-3.5%-2.0%36.8%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.01M17M13.72M17.2M28.49M
Short-term Investments72.64M42.19M7.18M131.86M134.78M
Net Receivables00001.5M
Inventory00000
Other Current Assets192.48K192.48K192K3.91M1.52M
Total Current Assets100.2M60.18M23.55M152.98M166.95M
Property, Plant & Equipment (Net)7M5.5M4.04M2.52M1.24M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets523.81K632.77K690K385K0
Total Non-current Assets7.53M6.13M4.73M2.9M1.24M
Total Assets107.73M66.31M28.27M155.88M168.2M
Account Payables1.78M2.17M3.18M4.79M2.22M
Short-term Debt3.86M3.15M16.21M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities133.71K36.87K39K2.28M2.86M
Total Current Liabilities17.01M12.64M31.89M11.82M20.69M
Long-term Debt15.64M15.98M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.21K22.21K44K00
Total Non-current Liabilities21.61M20.68M3.28M1.63M0
Total Liabilities38.62M33.32M35.18M13.45M20.69M
Common Stock12.52K41701K2K
Retained Earnings(349.73M)(392.08M)(436.68M)(476.89M)(555.43M)
Accumulated OCI(62.45K)(126.09K)(1K)35K(53K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity69.11M32.99M(6.91M)142.43M147.5M
Total Debt26.59M25.09M20.89M3.24M1.63M
Net Debt1.58M8.09M7.16M(13.96M)(26.86M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.